A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of AZD1775 on the Pharmacokinetics of Substrates for CYP3A, CYP2C19, CYP1A2 and to Provide Data on the Effect of AZD1775 on QT Interval in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 28 Jun 2018
At a glance
- Drugs Adavosertib (Primary) ; Caffeine; Granisetron; Midazolam; Omeprazole
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 19 Jun 2018 Planned End Date changed from 19 Jul 2018 to 22 Aug 2018.
- 19 Jun 2018 Planned primary completion date changed from 19 Jul 2018 to 22 Aug 2018.
- 19 Dec 2017 Planned End Date changed from 18 Jul 2018 to 19 Jul 2018.